Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes. Read full article: https://equity.guru/2021/06/21/core-one-cool-c-subsidiary-begins-development-of-psychedelic-drug-formulation-for-stroke-treatment/